Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UBX1325 in diabetic macular edema
NCT04857996Phase 2Completed
- Sponsor
- Unity Biotechnology
- Start
- Jun 2021
- Primary completion
- Apr 2023
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 2 trial of foselutoclax in diabetic macular edema (DME), sponsored by Unity Biotechnology. Started Jun 2021; status: completed.
02
Drugs
foselutoclax
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT04857996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04857996.